Navumab receives extended approval from the U.S. FDA for the treatment of lung cancer. On June 22, 2015, the U.S. FDA agreed to review Bristol-Myers Squibb’s PD-1 inhibitor OPDIVO nabumab as a treatment for patients with previously treated advanced squamous non-small cell lung cancer (NSCLC), and said it will review the drug’s marketing application under the priority review process. It has a good chance of being the first immunotherapy drug approved for advanced squamous non-small cell lung cancer. Opdivo nabumab indications and uses: OPDIVO nabumab is a human programmed death receptor-1 (PD-1) indicated for blocking antibody therapy in patients who: (1) have unresectable cargo metastatic melanoma and eprilimumab [ipilimumab] and, as in BRAFV600 mutation-positive, a BRAF inhibitor after disease progression. This indication was approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may depend on validation and the description of clinical benefit in the validation trial. (2) Metastatic squamous non-small cell lung cancer that has progressed with or after platinum-based chemotherapy.